Karen G. Anthony, Phd Email and Phone Number

17 years in drug discovery and development in the biotech environment, supporting academic translational efforts in multiple therapeutic areas, including anti-infectives, oncology, and autoimmunity. Evaluated academic research for translational and product development potential. Developed successful translational research proposals and led multiple drug discovery and development programs. Highlights include: Principal Investigator/ Program Director of National Institutes of Health (NIH)-funded co-operative research agreement. This was a 5-year, $8 million contract to discover and develop novel antibiotics. Established and managed a research consortium of academic institutions (Harvard, Univ. of Houston, Univ. of Oklahoma, Syracuse VA, and Univ. of Otago), two industry partners, multiple CROs, and ex-pharma drug development consultants. Led a multidisciplinary investigative team with expertise in high throughput screening, microbiology, cell biology, medicinal chemistry, structural biology, ADME, PK/Toxicology, and rodent models of infectious diseases (TB, MRSA, and anthrax).Principal Investigator/ Program Director of several NIH-funded Phase I and II Small Business Innovative Research projects (~$3 million) for discovery and development of small molecule anti-infectives (TB) and anti-inflammatory (RA, MS, and psoriasis) agents in collaboration with academic investigators.